Context: With prolonged life expectancy, we often encounter patients with elderly-onset type 2 diabetes mellitus (eT2DM). Although the clinical features of eT2DM are suggested to be different from those in patients with middle-age-onset type 2 diabetes mellitus (mT2DM), the islet pathologic features in eT2DM have not been addressed.
T he recent increase of elderly people has raised a great concern on the resulting socioeconomic burden in developed countries. The World Health Organization has defined "the aged society" as a society in which the population of people .65 years old is .7% (1) . Japan is a country with a superaged society composed of .25% of people aged $65 years (2) . Such a superaged society itself experiences high frequencies of a variety of age-related diseases with a reduced population of active workers.
The increase in the aged population has been directly linked to the increased prevalence of type 2 diabetes mellitus (T2DM) (3) . One-third of individuals aged .70 years are estimated to have signs of diabetes (4) . Diabetes in the elderly has been conventionally divided into two types depending on the time of diabetes onset: middle-age-onset T2DM (mT2DM) with long survival and elderly-onset T2DM (eT2DM) (3) . It has been proposed that the clinical treatment of patients with eT2DM should be considered separately from those with mT2DM, because eT2DM patients are susceptible to hypoglycemia (5) , and those with mT2DM more commonly develop retinopathy (6) . Although the pathological changes in the pancreas in mT2DM are characterized mainly by a reduced b-cell area and an increased a-cell area (7) (8) (9) (10) (11) , the islet pathologic features in eT2DM have not been specifically addressed.
To provide the appropriate care and treatment, it would be important to characterize the islet pathologic features in eT2DM. Exploration of the pathological changes in the pancreas in eT2DM could enable us not only to better understand the underlying pathophysiology for elderly patients with T2DM but also to determine the ideal therapeutic guidelines.
Materials and Methods

Subjects
In the present study, we collected pancreatic tissue from 13 young subjects without T2DM (yND; age, 25.8 6 0.9 years; mean 6 standard error), 27 mT2DM subjects (age, 63.2 6 2.3 years; age at T2DM onset, 48.3 6 2.3 years), 22 middle-age subjects without T2DM (mND; age, 61.3 6 1.4 years), 15 subjects with eT2DM (age, 88.0 6 0.6 years; age at T2DM onset, 80.8 6 1.4 years), and 30 superelderly subjects without T2DM (eND; age, 89.5 6 0.7 years; Table 1 ). In the mT2DM group, 4 had survived a long period, with an average age at death comparable to the average age of the eT2DM group (age, 85.5 6 0.5 years; age at T2DM onset, 56.0 6 2.7 years). The investigated cases were limited to fresh autopsy cases conducted within 5 hours after death. Cases with other diseases or a history of medications that could influence the data were excluded from the evaluation. The pancreatic weight was measured after fine dissection of the organ from the duodenum or other surrounding tissues. The adipose tissue that rimmed the pancreas, surrounding the pancreas parenchyma, was considered the border, and extra fat was trimmed off and then weighed. The clinical records were extracted in each case to record the last evaluation of body weight and height to calculate the body mass index (BMI), diabetes duration, diabetes treatment, and age at T2DM onset, estimated from the time of diagnosis (Supplemental Table 1 ). Cases with a history of hyperglycemia were considered to have T2DM because hyperglycemia fulfills the criteria for T2DM proposed by the Japan Diabetes Society (12) . The diagnosis of T2DM in the diabetic groups was further confirmed by the clinical records of the patients. Subjects were excluded if potential secondary causes of T2DM were present, they had been exposed to chronic glucocorticoid treatment, or the pancreatic tissue had undergone marked autolysis or showed evidence of striking pancreatitis. Cases with other disorders that could have influenced the data were also excluded from the evaluation. The subjects chosen as age-matched nondiabetic controls fulfilled the criteria of "normal type" without a previous or family history of T2DM.
At autopsy, after dissection of the pancreas and measurement of the weight, the pancreata were immersed in 10% buffered formalin for 48 to 72 hours and then dissected into two portions each of the head, body, and tail. The ethics committee of the Hirosaki University School of Medicine approved the use of paraffin blocks and the study design (approval no., 2013-235), and the study conformed to the provisions in the Declaration of Helsinki.
Pathological evaluation
From the paraffin blocks, several consecutive 4-mm-thick sections were obtained and stained with conventional hematoxylin and eosin. Because the structural integrity was preserved most consistently in the pancreatic body area, the data from the body represent the values in individuals in the present study, as previously described (7, 9 ). An examination of the pathological changes in the pancreas from mT2DM and eT2DM subjects disclosed lesions in the islets and exocrine pancreas, the latter of which was represented by stromal inflammatory changes, atrophic changes of acinar tissues, interstitial fibrosis of lobules, fatty infiltration into the lobules and interlobular areas, arteriosclerotic changes of nutrient arteries, and ductal lesions. Azan-Mallory trichrome stains were applied to evaluate the extent of stromal fibrosis. Duct lesions were represented by obstruction or dilatation with or without epithelial hyperplasia (often transformed into dysplastic changes). Vascular tissues showed atherosclerotic and hyalinous changes with narrowing of the lumen. The changes in these six factors were semiquantitatively graded as none (grade 0) if no marked pathological changes were identified; as mild (grade 1) if focal inflammatory cell infiltration, focal acinar cell atrophy showing flattening, ductulization, slight interstitial fibrosis, mild fatty changes only in the peripheral area of lobules, mild medialintimal thickening of the arteries, and slight narrowing or dilation of the duct with focal epithelial hyperplasia were present; moderate (grade 2) if scattered areas of stromal infiltration of inflammatory cells, scattered foci of acinar cell atrophy, interstitial fibrosis infiltrating into lobules, fatty changes in the peripheral and focal intralobular acini, moderate atherosclerotic arteriosclerosis, and narrowing ducts or moderate dilatation with foci of papillary epithelial hyperplasia were present; and severe (grade 3) if diffuse but modest infiltration of inflammatory cells, diffuse acinar cell atrophy, extensive intralobular fibrosis, fatty infiltration into diffuse intralobular acini, marked atherosclerosis, and obstruction or wide dilatation of ducts with marked hyperplasia or dysplasia were present. Each pathological item was scored as 0, 1, 2, or 3 in individual subjects, and the average score was obtained for each group. The scoring was conducted by two pathologists in blinded fashion (H.M. and S.Y.). Among 107 cases with 6 factors (of a total of 642 subjects), disagreement in the grading occurred in 7 cases (6.5%) for inflammation, 9 cases (8.4%) for acinar atrophy, 11 cases (10.2%) for fibrosis, 15 cases (14.0%) for fatty infiltration, 12 cases (11.2%) for atherosclerosis, and 8 cases (7.5%) for ductal lesions. The group comparison for each pathological feature was performed by deleting the cases with discordant decision, although the differences of the two observers were rather minor with scores of 1 or 2. The scores for other measures in these cases were used for group comparison.
Morphometry of islet and detection of amyloid
For the determination of islet area, the sections were incubated with monoclonal antibody to chromogranin A (1:1000; Dako Cytomation, Glostrup, Denmark) overnight, followed by incubation with alkaline phosphatase-labeled rabbit anti-mouse immunoglobulin (1:1000; Dako Cytomation). The reaction products were colorized with Vulcan Fast Red Chromogen Kit (Biocare Medical, LLC, Concord, CA) and examined using a fluorescent microscope. The fractional islet area relative to the total pancreatic parenchymal area (including endocrine and exocrine pancreas and stroma), defined as the islet volume density (V i ), was measured using the point-counting method on $1000 islets in each subject using ImageJ software, version 1.56 (National Institutes of Health, Bethesda, MD), as described previously (7, 9) . The total islet mass (M i ) was obtained by multiplying the V i by the pancreatic weight. The number of islets (density of islets) per unit area was obtained by counting the number of chromogranin A-positive areas. We separately counted the number of small-size islets composed of three cells or less, considered as so-called neogenic islets (13, 14) , regardless of whether their location was near the duct or within the acinar tissue (13, 14) . The density of the neogenic islet per unit parenchymal area and the rate of neogenic islets among the total islet number were also calculated for each subject. The average size of the islet was obtained by dividing the total islet area by the number of islets.
For identification and measurement of the amyloid area, we conducted double immunofluorescence staining for Chromogranin A (red fluorescence) and thioflavin-T staining (Wako Pure Chemicals, Osaka, Japan), which showed positive green fluorescence on fluorescent microscopy (Axio-Imager M1; Carl Zeiss, Tokyo, Japan). Amyloid-positive areas were measured using the point-counting method on $100 islets in each individual and expressed as the percentage area of pancreatic parenchyma, yielding the values of amyloid volume density relative to the area of pancreas parenchyma (V amy ). Values of pancreatic amyloid mass were then obtained by multiplication of the V amy by the pancreatic weight for each case, and the mean values were calculated in each group.
Morphometric analysis of islet endocrine cells
To characterize the composition of islet endocrine cells in each case, we conducted simultaneous immunostaining of four endocrine hormones: insulin, glucagon, somatostatin, and pancreatic polypeptide (PP). Antibodies for these hormones were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) for insulin, Dako Cytomation for glucagon and somatostatin, and the Immunobiological Laboratory, Ltd. (Gunma, Japan) for PP. The staining procedure was previously reported (9) . Thereafter, the sections were lightly counterstained with hematoxylin. For determination of the fractional b-, a-, d-, and PP-cell area relative to the pancreatic parenchymal area (V b , V a , V d , and V PP , respectively), the pancreatic sections were imaged at magnification of 340. V b , V a , V d , and V PP were quantified at point count basis using ImageJ (National Institutes of Health) (9, 15) . In each case, $100 islets were examined. When the pancreatic weight was available, the Mi,
, and PP-cell mass were obtained by multiplication of the V i , V b , V a , V d , and V PP , respectively, by the pancreatic weight.
Proliferation activity and apoptosis of b-cells
To estimate the proliferating activity of b-cells, we conducted simultaneous immunostaining using antibodies to islet endocrine cells and Ki67 (MIB-1; Dako Cytomation), as previously reported (9, 15, 16). Cells double-positive for each hormone and Ki67 (among .500 endocrine cells) were counted in each subject, and the mean value was calculated for each group.
To explore the cell death, or viability of b-cells, we adopted double immunostainings of anti-insulin with terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) of an ApopTag (EMD Millipore, Bellerica, MA), as previously described (9, 16) .
Statistical analysis
Data are presented as the mean 6 standard error. Statistical comparisons of the mean values among the groups were performed using analysis of variance with post hoc Bonferroni corrections (version 5.0.1; StatView, Mountain View, CA). Simple regression analysis was performed for the correlation analysis. The Wilcoxon rank sum test was performed to compare endocrine cell replication between groups owing to the skewed distributions of the observations. P , 0.05 was considered to indicate statistical significance.
Results
Clinical data
The major clinical profiles of the investigated cases are summarized in Table 1 . Detailed clinical data for each case are described in Supplemental Table 1 . The average BMI was comparable among all groups (range, 20 to 23 kg/m 2 ). The age at T2DM onset was 48.3 6 2.4 years in the mT2DM group. The age at T2DM onset in the eT2DM group was 80.8 6 1.4 years (P , 0.01 vs mT2DM). The range of T2DM duration was wide in the mT2DM group (1 to 35 years), and the average was longer than that in eT2DM. No statistically significant difference was detected, however, in the hemoglobin A1C values (NGSP [formerly, National Glycohemoglobin Standardization Program]) between the mT2DM and eT2DM groups. The pancreatic weight was markedly decreased in eT2DM by nearly one-half (70.4 6 4.3 g) compared with that in the other groups (P , 0.01 vs for all).
Pathological features of eT2DM
Screening for pancreatic histologic features disclosed that features of yND and mND were more or less similar, except for arteriosclerotic changes in mND (Fig. 1) . Fat deposition in the pancreas was robust in the mT2DM and eT2DM groups but much less in their nondiabetic counterparts (Fig. 1) . In contrast, the eT2DM group showed marked acinar cell atrophy of the pancreatic parenchyma and interstitial fibrosis. Such atrophy and fibrosis were modest in the mT2DM group. Ductal dilatation or obstruction with epithelial hyperplasia or dysplasia was most conspicuous only in the eT2DM group (Fig. 1) . Ductal obstruction or dilatation was not apparent in the mT2DM group. In addition, stromal inflammatory cell infiltration was not marked in any group. Semiquantitative evaluation of these pathological changes demonstrated that extra-islet pathologic features in the eT2DM group was characterized by acinar cell atrophy, stromal fibrosis, atherosclerosis, and obstructive ductal lesions with epithelial hyperplasia or dysplasia (Fig. 1) .
Morphometric analysis of islets and islet endocrine cells
A substantial increase was found in the density of the total islets in the eT2DM group compared with the mT2DM and eND groups (P , 0.01 for both), which showed a greater islet density than that in the mND group (P , 0.01; Table 2 ). The average islet size was smaller in the mT2DM and eT2DM groups than their respective nondiabetic counterparts (P , 0.05 for both). The density of neogenic islets was increased in the mT2DM and eT2DM groups compared with their age-matched nondiabetic groups (P , 0.05 and P , 0.01, respectively; Table 2 ). The latter was also greater than the former (P , 0.05). The rate of neogenic islets among the total number of islets was more than one-half in nondiabetic groups and significantly increased in the mT2DM group compared with the mND group (P , 0.01). In contrast, no increase was found in the population of neogenic islets in the eT2DM group, which was significantly reduced compared with that in the mT2DM group (P , 0.01).
No substantial difference was found in the V i among all the groups with considerable overlap, although a trend was seen toward a decrease in the mT2DM and eT2DM groups compared with nondiabetic groups (Fig. 2) . Consistent with previous results (7, 9), we found an approximately 30% reduction of V b in the mT2DM group compared with the mND group. A reduction of V b in the eT2DM group was similar to that observed in the mT2DM group. V a was increased (approximately 15%) in the mT2DM group compared with the mND group (P , 0.05) but was reduced in the eT2DM group compared with the eND group. No substantial differences were found in V d or V PP among all the groups.
A substantial M i reduction was found in the eT2DM group compared with the eND group but was not significantly altered in the mT2DM group. Consistent with V b , the M b was significantly reduced in the mT2DM and eT2DM groups compared with their respective nondiabetic controls. In contrast, M a was not significantly increased in the eT2DM group compared with the eND group and was increased in the mT2DM group. M d was not altered in the mT2DM group but was significantly decreased in the eT2DM group.
Islet amyloid
Islet amyloid deposition was marked in most cases of eT2DM [V amy , 0.35% 6 0.10%; Fig. 3(a) ]. The amyloid Fig. 3(a) ]. The eND group also had a small amount of amyloid deposition; however, V amy (0.02% 6 0.01%) was much less than that in the eT2DM group. Similarly, the amyloid mass was most marked in the eT2DM group, which was 3.4-fold that of the mT2DM group [ Fig. 3(b) ]. An inverse correlation was found between V b and V amy (r = 0.52, P , 0.05) but no statistically significant correlation was found between V amy and BMI [r = 0.26; Fig. 3 (c) and
Proliferating activity and apoptotic cells
No substantial difference was found in the population of islet endocrine cells positive for Ki67 (approximately 0.16% to 0.19%) between the diabetic and nondiabetic groups ( Table 2) . Although some acinar cells were positive for TUNEL, no apparent positive cells were identified in the islets in any of the groups.
Discussion
In the present study, to the best of our knowledge, we have characterized for the first time distinct pathological findings in the eT2DM pancreas. The salient features were marked atrophy of the pancreatic parenchyma, ductal obstruction or dilatation with epithelial hyperplasia and dysplasia, interstitial fibrosis, fat infiltration, reduction of V b and M b , and marked amyloid deposition in the islets. It has generally been accepted that pancreatic atrophy is common in type 1 diabetes mellitus (17) (18) (19) , although it is still controversial in mT2DM (20) (21) (22) . We found mild fat infiltration, fibrosis, and atrophy of the exocrine tissues in the eND group, which were comparable with previous reports (16) . The extent of such alterations was much more prominent in the eT2DM group. Robust alterations of exocrine pancreatic changes can be attributed to ductal lesions with distal exocrine atrophy or ischemia due to coexistent arteriosclerosis and diabetes-related vascular dysfunction (19, 23) . Serum concentrations of amylase were slightly elevated in this group, suggesting the presence of incipient pancreatic exocrine dysfunction. In cases with pancreatic diabetes, massive fibrosis and pancreatic atrophy accompanied by b-cell deficits were widely acknowledged (24, 25) . The main pathologic feature of chronic pancreatitis is obstruction of the pancreatic ducts due to stone or protein plugs. In turn, focal inflammatory changes can disturb islet function and structure, resulting in the onset of (22) diabetes (24) . In addition, insufficient insulin secretion can result in acinar tissue atrophy because of the lack of its trophic action on the peri-insular acinar cells (18, 19) . Taken together, our results suggest that an exocrine component might be present in the disease course of eT2DM and/or that it shares some features with pancreatic diabetes but that it does not truly resemble the diabetes that develops secondary to profound exocrine pancreatic disease. In our previous studies, islet amyloid deposition was found in approximately 30% of Japanese patients with mT2DM (7, 15) , although it was found 90% of white T2DM patients (26) . The extent of amyloid deposition (V amy ) correlated well with an increase in BMI and decrease in V b (15) . In the present study, we have confirmed that V amy inversely correlates with V b in eT2DM. No substantial relationship was found, however, between V amy and BMI in the eT2DM group. Although it was shown that V b was increased in obese nondiabetic white patients (8, 27) , this was not the case in Japanese with a high BMI (16, 28) . In our cohort, the eT2DM group mostly included nonobese subjects (mean BMI, 21.4 kg/m 2 ). Hence, the dissociation of the relationship between V amy and BMI in eT2DM can be ascribed to the limited number of obese subjects or, at least in part, to ethnic reasons. Alternatively, the amyloid deposition in eT2DM might develop differently from that in mT2DM. Although the small number of subjects in the present investigation and lack of information on islets in white superelderly did not allow for speculation, ischemia or age-related tissue degeneration related to insulin resistance might contribute to the process of amyloid deposition in eT2DM.
Our morphometric data have demonstrated that pancreatic weight is crucial to determining the total cellular mass of the islet or each endocrine cell. Although the V i of eT2DM was not different from that of eND, the M i in eT2DM was significantly smaller than that in eND. Also, in contrast to increases in V a and M a in mT2DM, M a was decreased in eT2DM. The question regarding whether the susceptibility of eT2DM is related to hypoglycemia or hypoglucagonemia requires future investigations. However, information on the changes in pancreatic weight is sparse in previous studies. Saisho et al. (29) reported that the pancreatic weight calculated on computed tomography images was reduced with aging in American subjects. In contrast, our studies on the pancreatic weight measured at autopsy could not confirm such findings (16) . The reason for this discrepancy is not clear but could have resulted from different methods for measurement. Difficulty in determining the pancreatic border in the aged pancreas rich in fatty tissues using imaging studies could also account for such discrepancy (21, 30) .
The islet endocrine cell volume density or mass is mainly dependent on the rate of islet neogenesis and cell death (8, 9, 11) . In the present study, despite an increased density of neogenic islets, both V b and M b were significantly reduced in eT2DM. We could not identify a decreased rate of endocrine cell proliferation as determined by Ki67 staining or an increased rate of apoptotic endocrine cells by TUNEL staining. These negative results might contradict the results from other investigators who showed a greater proliferation rate or increased apoptosis in the islets of the diabetic pancreas (8, 10) . As reported previously (7, 10, 16), we believe this finding did not result from technical errors because simultaneous staining on the same slides succeeded well in the detection of apoptotic cells in the lymph tissues or sparse acinar cells undergoing apoptosis and in Ki67 + proliferating cells in inflammatory lymph tissues or regenerating intestinal mucosa. It is thus likely that the reduced V b and M b in eT2DM might not have resulted from the drastic process of cell death but possibly reflect impaired replication of b-cells. In keeping with this contention, the rate of neogenic islets among the total islets in eT2DM compared with eND or mT2DM might reflect reduced islet cell replication, although they also contain cells, not necessarily related to islet neogenesis (13, 14) . We admit that it should have been necessary to compare the clinical profile and islet pathologic features between patients with eT2DM and critically age-matched mT2DM patients with longer survival. However, it was not possible for us to obtain a sufficient number of such patients with an extremely long history of T2DM because most patients with mT2DM do not survive sufficiently long enough for comparison with eT2DM patients. However, the pancreatic pathologic features in the 4 cases with mT2DM and long-term survival whose ages were matched to those with eT2DM were more or less similar to those in the conventional mT2DM group. Currently, the average lifespan of patients with T2DM is 65 to 70 years and 71 to 75 years for men and women, 12.8 and 12.2 years shorter than that for men and women without T2DM, respectively (31, 32) . The average age at death for those with eT2DM was 88.5 years in the present study and .10 years longer than the standard in developed countries. It is not known at present whether the lifespan of those with eT2DM becomes shorter after the onset of T2DM than that in the eND group without T2DM. Meticulous long-term follow-up in the future might be able to uncover whether the presence of diabetes influences the clinical outcomes of patients with eT2DM.
A number of limitations exist for interpretation of the results in the present study. Because our study was retrospective in nature, characterization of the clinical profile of those with eT2DM is immature and more information on the digestive functions related to exocrine pancreatic pathologic features must be collected. Currently, our method is not sufficient enough to analyze the molecules related to aging, in part owing to difficulty in obtaining high-quality nucleic acids or proteins from human autopsy samples. Laser-captured microdissection of the islets might be one solution; however, enough highquality RNA to analyze gene expression from archival paraffin-embedded tissues has not been achieved. The development of new techniques or the accumulation of fresh samples could solve this issue in the future.
